Administrative & Regulatory Investigations (SEC, FDA, FINRA)

Administrative & Regulatory Investigations (SEC, FDA, FINRA) Overview

Administrative and regulatory investigations are not routine compliance matters—they are serious government inquiries that can threaten careers, licenses, companies, and reputations built over decades. When agencies such as the Securities and Exchange Commission (SEC), Food and Drug Administration (FDA), or Financial Industry Regulatory Authority (FINRA) initiate an investigation, the outcome often hinges on how the matter is handled in its earliest stages.

At Chapman, Dowling & Mallek, we view these investigations for what they truly are: inflection points. A misstep, delayed response, or poorly framed explanation can escalate a regulatory inquiry into enforcement actions—or even criminal exposure. A disciplined, strategic response can just as often result in quiet resolution, reduced penalties, or no action at all.

Understanding the process, the risks, and the agency mindset is essential to protecting both your position and your future.

What Administrative & Regulatory Investigations Involve — From a Legal Perspective

From a legal standpoint, administrative and regulatory investigations are structured fact-finding efforts. Agencies and self-regulatory organizations initiate them to determine whether an individual or entity has violated statutes, regulations, or professional standards within their jurisdiction.

Unlike criminal investigations, which focus on intent and punishment, regulatory investigations are designed to enforce compliance, protect markets or public health, and correct perceived misconduct. That distinction, however, does not mean the consequences are minor.

These investigations typically involve:

• Information Demands
  Requests for documents, data, emails, financial records, and internal communications—often accompanied by subpoenas or compulsory process.
• Interviews and Testimony
  Executives, compliance officers, physicians, brokers, and employees may be questioned under oath, with statements later used to support enforcement actions.
• Agency Review and Analysis
  Enforcement attorneys and subject-matter specialists scrutinize the evidence against industry-specific regulations and standards.
• Enforcement Proceedings
  If violations are alleged, agencies may pursue civil penalties, industry bars, license suspensions, or cease-and-desist orders.
• Negotiated Resolutions
  Many matters are resolved through settlements—often without admissions—when handled strategically and early.

Each agency operates under its own statutory framework. What constitutes a violation for one regulator may not apply to another, making industry-specific defense experience critical.

Common Allegations in SEC, FDA & FINRA Investigations

Securities and Exchange Commission (SEC)

The SEC regulates U.S. securities markets and aggressively enforces violations involving public companies, executives, investment professionals, and issuers. Common allegations include:

• Insider trading
• Securities fraud and misrepresentations
• Market manipulation
• Accounting and financial reporting fraud
• Broker-dealer misconduct, including churning or unsuitable recommendations

Food and Drug Administration (FDA)

The FDA oversees products that directly impact public health. Investigations often target manufacturers, healthcare companies, and executives for:

• Adulterated or misbranded drugs or devices
• Marketing unapproved products
• Good Manufacturing Practice (GMP) violations
• Off-label promotion
• Clinical trial and data integrity violations

Financial Industry Regulatory Authority (FINRA)

FINRA regulates broker-dealers and registered representatives. Allegations commonly include:

• Unauthorized trading
• Excessive trading or churning
• Misappropriation of client funds
• Failure to supervise
• Suitability and disclosure violations

Who Conducts These Investigations

• SEC — Division of Enforcement
• FDA — Office of Criminal Investigations (OCI) and compliance divisions
• FINRA — Department of Enforcement

Importantly, regulatory agencies frequently coordinate with criminal authorities such as the Department of Justice (DOJ) and the Federal Bureau of Investigation (FBI). What begins as a civil or administrative inquiry can quickly evolve into a criminal referral if not carefully managed.

Penalties and Consequences

Adverse outcomes in administrative and regulatory investigations can be severe and lasting:

Financial Exposure

• Significant civil fines and penalties
• Disgorgement of profits
• Restitution to investors, patients, or consumers

Professional Impact

• Permanent or temporary industry bars
• License suspension or revocation
• Loss of board positions or executive roles

Operational Restrictions

• Cease-and-desist orders
• Mandatory compliance overhauls
• Ongoing regulatory monitoring

Criminal Risk

• Referral for prosecution, potentially resulting in indictment and incarceration

Just as damaging—often more so—is the reputational harm that follows public enforcement actions.

Administrative & Regulatory Investigations (SEC, FDA, FINRA) Specific Statutes &
Regulations

• Securities Exchange Act of 1934 – SEC enforcement authority
• Food, Drug, and Cosmetic Act (FDCA) – FDA regulatory authority
• FINRA Rules and Regulations – Financial industry compliance
• Administrative Procedure Act (APA) – Procedures governing administrative investigations
• Dodd-Frank Act – Whistleblower program and enforcement

Need help now? Call our government and federal investigations defense attorneys today.

Executives, professionals, and organizations trust us because we understand how federal agencies build investigations, move quickly to protect rights and positions, and focus on achieving the best possible outcome with minimal disruption to careers, operations, and reputations.
346-CHAPMAN

Why Experienced Counsel Matters in Regulatory Investigations

Administrative and regulatory investigations are not the time for reactive decision-making or informal explanations. Every document produced, every statement given, and every strategic choice shapes the outcome.

At Chapman, Dowling & Mallek, we intervene early, control the narrative, and engage regulators from a position of strength. Our role is to:

• Protect clients during interviews and testimony
• Shape document productions strategically
• Prevent unnecessary escalation
• Pursue discreet, favorable resolutions whenever possible
• Defend aggressively if enforcement becomes unavoidable

Related Official Government & Regulatory Sources

• SEC Division of Enforcement
• FDA Office of Criminal Investigations
• FINRA Enforcement
• HHS Office of Inspector General – Health Care Fraud